Prognostic value of insulin-like growth factor-1 receptors in patients with colon/rectal cancer: correlation with plasma prolactin.
Prognostic value of IGF-1 receptors (IGF-1R) was evaluated and compared with circulating prolactin (PRL) in 59 patients with Dukes B or C colon/rectal cancer. IGF-1R was estimated by radioligand binding assay and PRL was estimated by immunoradiometric assay. Eighty-five percent (50/59) of patients had IGF-1R- tumours while IGF-1R positivity was observed in only 15% (9/59) of patients. None of the clinicopathological parameters showed any association with IGF-1R status. No significant difference was observed in overall survival period between patients with IGF-1R+ tumours and those with IGF-1R- tumours. However, a significant difference in overall survival time was observed between patients with PRL < 20.0 and > 20.0 ng/ml plasma (X2 = 4.70, df = 1, P < 0.05). In bivariate analysis, patients with IGF-1R- tumours and concomitant hyperprolactinemia had unfavourable prognosis compared to their counterpart (X2 = 4.21, df = 1, P < 0.05). We conclude that there was a trend of better overall survival in patients with IGF-1R+ tumours, and PRL < 20.0 ng/ml plasma when compared to patients with IGF-1R- tumours, and PRL > 20.0 ng/ml plasma. Further, IGF-1R negativity in conjunction with hyperprolactinemia could be used as an indicator of unfavourable prognosis in patients with Dukes B or C colon/rectal cancer.
Division of Research, Gujarat Cancer & Research Institute, Gujarat Cancer Society, Asarwa, Ahmedabad, India.
J M
JM
Bhatavdekar
D D
DD
Patel
N G
NG
Shah
N H
NH
Karelia
H H
HH
Vora
N
N
Ghosh
T P
TP
Suthar
D B
DB
Balar
D000328:Adult; D000704:Analysis of Variance; D016009:Chi-Square Distribution; D015179:Colorectal Neoplasms / Q000097:blood / Q000378:metabolism* / Q000473:pathology; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009367:Neoplasm Staging; D011237:Predictive Value of Tests; D011379:Prognosis; D011388:Prolactin / Q000097:blood*; D017526:Receptor, IGF Type 1 / Q000032:analysis*; D016019:Survival Analysis
D011388:Prolactin; D017526:Receptor, IGF Type 1